Tamiflu Safety Information
There is no evidence for the efficacy of Tamiflu Protecion Against Influenza And Avian Flu in any illness other than influenza types A and B. Treatment efficacy in high-risk patients (chronic cardiac disease and/or respiratory disease) has not been established, and there were no differences in the incidence of complications between treatment and placebo groups in this population. The safety and efficacy of repeated treatment or prophylaxis courses have not been established.
In treatment studies in adult patients, adverse events occurring more frequently in patients taking Tamiflu Protecion Against Influenza And Avian Flu compared with placebo (incidence >1%) were nausea, vomiting, bronchitis, insomnia and vertigo.
In treatment studies in pediatric patients, the most frequently reported adverse event occurring in >1% of patients receiving Tamiflu Protecion Against Influenza And Avian Flu was vomiting. Other events reported more frequently by pediatric patients treated with Tamiflu Protecion Against Influenza And Avian Flu included abdominal pain, epistaxis, ear disorder and conjunctivitis. These events generally occurred once and resolved despite continued dosing.
In prophylaxis studies in adult patients and adolescents aged 13 years and older, adverse events were qualitatively very similar to those seen in the treatment studies, despite a longer duration of dosing. Events reported more frequently in subjects receiving Tamiflu Protecion Against Influenza And Avian Flu compared to subjects receiving placebo in prophylaxis studies included nausea, vomiting, diarrhea, abdominal pain, dizziness, headache, insomnia, vertigo and fatigue.
Vaccination is considered the first line of defense against influenza.